Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OstEvo - Osteosarcoma Evolves
NCT07477457Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib, trametinib, disulfiram, sunitinib in osteosarcoma (OS), sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2026; status: recruiting.
02
Drugs
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT07477457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477457.